19-20 November, Vilnius: The main aim of the annual Conference, which will be held under the auspices of the Lithuanian Presidency of the Council of the EU, is to identify the existing best evidence on fostering the development of sustainable health systems throughout the entire Europe.
The question of what information – if any – should be defined as commercially confidential remains in dispute and this could hinder progress in creating a balanced, practical and trusted system for handling requests for data.
Research by the ABPI indicates current statistics on the state of play in transparency are not accurate. A toolkit will guide members in complying with disclosure requirements and generate more reliable information on compliance.
Providing controlled access to identified patient-level information is an essential element of realising the full potential of clinical data stores.
The current polarised debate is not helpful to anyone, least of all patients, says Alastair Kent of Genetic Alliance UK.
After setting out principles under which the industry is prepared to open up clinical study reports, the European Federation of Pharmaceutical Industries and Associations (EFPIA) is trying to reach a consensus with campaigners and regulators on how they should be applied in practice.
August 27th, 2013 Brussels
EFPIA and the Pharmaceutical Research and Manufacturers of America (PhRMA) have issued a joint proposal to enhance responsible clinical trial data sharing. What does this mean practically for research in Europe, and what are the best practices for implementation?
4 September 2013, Webinar:
Vital Transformation's inaugural webinar discusses its latest peer reviewed research on WBMRA technology helping stratify diagnosis and increase efficiency in the treatment of ischemic cardio vascular disease.